Parnassus Investments released its second-quarter 2025 investor letter, reporting a net return of 7.24% outperforming the Russell 1000 Value Index. The letter lists the top 5 holdings of the Parnassus Value Equity Fund, including Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), which saw a 1.57% rise in the past month and closed at $556.56 on August 12, 2025.

The investor letter highlights Regeneron Pharmaceuticals’ attractive risk/reward profile, emphasizing its long-term growth potential driven by intellectual property, research capabilities, and product launches. Despite not being among the 30 most popular stocks among hedge funds, 66 hedge fund portfolios held positions in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), which recently beat earnings expectations with an EPS of $12.89.

For more insights on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), check out BMO Capital’s views in another article and visit the hedge fund investor letters Q2 2025 page for additional investor letters from leading investors.

Read more at Yahoo Finance: Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares